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Abstract 
SURVIVAL PREDICTION FOR BRAIN TUMOR PATIENTS USING GENE EXPRESSION 
DATA 
Vinicius Bonato, B.S., Universidade Estadual de Campinas, Campinas, SP, Brazil; 
M.Sc., Universidade Estadual de Campinas, Campinas, SP, Brazil; 
Ph.D., Universidade Estadual de Campinas, Campinas, SP, Brazil; 
Supervisory Professor: Dr. Kim-Anh Do 
 Brain tumor is one of the most aggressive types of cancer in humans, with an estimated 
median survival time of 12 months and only 4% of the patients surviving more than 5 years after 
disease diagnosis. Until recently, brain tumor prognosis has been based only on clinical information 
such as tumor grade and patient age, but there are reports indicating that molecular profiling of 
gliomas can reveal subgroups of patients with distinct survival rates. We hypothesize that coupling 
molecular profiling of brain tumors with clinical information might improve predictions of patient 
survival time and, consequently, better guide future treatment decisions. In order to evaluate this 
hypothesis, the general goal of this research is to build models for survival prediction of glioma 
patients using DNA molecular profiles (U133 Affymetrix gene expression microarrays) along with 
clinical information. First, a predictive Random Forest model is built for binary outcomes (i.e. short 
vs. long-term survival) and a small subset of genes whose expression values can be used to predict 
survival time is selected. Following, a new statistical methodology is developed for predicting time-
to-death outcomes using Bayesian ensemble trees. Due to a large heterogeneity observed within 
prognostic classes obtained by the Random Forest model, prediction can be improved by relating 
time-to-death with gene expression profile directly. We propose a Bayesian ensemble model for 
survival prediction which is appropriate for high-dimensional data such as gene expression data. Our 
approach is based on the ensemble "sum-of-trees" model which is flexible to incorporate additive 
and interaction effects between genes. We specify a fully Bayesian hierarchical approach and 
illustrate our methodology for the CPH, Weibull, and AFT survival models. We overcome the lack 
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of conjugacy using a latent variable formulation to model the covariate effects which decreases 
computation time for model fitting. Also, our proposed models provides a model-free way to select 
important predictive prognostic markers based on controlling false discovery rates. We compare the 
performance of our methods with baseline reference survival methods and apply our methodology to 
an unpublished data set of brain tumor survival times and gene expression data, selecting genes 
potentially related to the development of the disease under study. A closing discussion compares 
results obtained by Random Forest and Bayesian ensemble methods under the biological/clinical 
perspectives and highlights the statistical advantages and disadvantages of the new methodology in 
the context of DNA microarray data analysis. 
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1. Introduction 
 
Glioma is a type of central nervous system (CNS) cancer affecting the glial cells (Cairncross et 
al., 1998). Glial cells are responsible for building the neuronal myelin sheath, forming the CNS structural 
tissue, and providing physical protection to adjacent neuronal cells (Junqueira & Carneiro, 2005). Glioma 
is the most frequent (~40%) type of primary brain tumor (PBT), with an average of worldwide annual 
occurrence close to 190,000 cases (Castells et al., 2009) resulting in more than 140,000 deaths each year 
with 10,000 of them occurring only in the United States (Nutt et al., 2003). Despite major efforts to 
reduce deaths caused by this disease, the mean survival time of newly diagnosed malignant glioma 
patients remains at approximately 12 months (Furnari et al., 2007) and after 24 months of surgical 
resection nearly 90% of patients are dead (Louis et al., 2007; Nutt et al., 2003). In the list of deaths 
caused by cancer, gliomas are ranked in first for children under the age of 15 years and are ranked in 
second for individuals ranging from 15 to 34 years of age (Castells et al., 2009). 
 Glioma mainly develops in the brain and is usually classified based on the glial cell type 
primarily affected by the tumor such as astrocytomas (astrocytes), oligodendrogliomas (oligodendrocytes) 
or oligoastrocytomas (astrocytes and oligodendrocytes)(Louis et al., 2007). There is a common sense in 
the literature supporting the idea that neurodevelopment and gliomas are highly related. Supposedly, 
malignant gliomas originate from uncontrolled neural stem/progenitor cells located in the forebrain which 
manifest mesenchymal phenotypes and become able to invade surrounding tissues (Bachoo et al., 2002; 
Carro et al., 2010; Phillips et al., 2006). The typical glioma phenotype, which includes invasion, 
proliferation, migration, necrosis, and angiogenesis, is triggered by factors present in the adjacent 
extracellular matrix (ECM) and by the abnormal production of cell surface growth-factor receptors (Giese 
et al., 2003). High tumor recurrence (95%), in spite of adjuvant therapies such as surgical removal 
followed by chemotherapy and/or radiotherapy, is attributed to the capacity that putative cancer stem cells 
have to infiltrate the normal surrounding parenchyma of the main tumor areas, making complete removal 
rarely possible (Giese et al., 2003).  
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1.1. Glioma classification and diagnosis 
Following the WHO grading system, gliomas can be classified on the basis of histopathological 
features as (I) slow-growing, circumscribed, benign tumors which can be surgically removed, (II) diffuse 
slow-growing tumors presenting well-differentiated cells which due to its propensity of infiltration can 
turn the cancer incurable by surgery, (III) diffuse anaplastic tumors characterized by atypical nuclei and 
significant proliferative activity with the capacity of infiltrating extensively throughout the brain 
parenchyma being more fatal than lower-grades, and (IV) neoplasm with more characteristics of 
malignancy such as predominance of undifferentiated cells, vascular proliferation, atypical nuclei, cellular 
polymorphism (hence the name multiforme), high proliferative activity, and tissue necrosis (Furnari et al., 
2007; Louis et al., 2007). The majority of malignant gliomas are specifically subtyped as: diffuse 
astrocytoma (WHO Grade II), anaplastic astrocytoma (III), glioblastoma multiforme (IV), 
oligodendroglioma (II), anaplastic oligodendroglioma (III), oligoastrocytoma (II), and anaplastic 
oligoastrocytoma (III). 
Diffuse astrocytoma (DA) typically occurs in young adults (30 – 40 years of age) and is 
commonly located in the supratentoral brain region. DA has an inherent tendency to become anaplastic 
and, eventually, progress to glioblastoma multiforme. DA has an annual incidence rate of 1.4 new cases/1 
million population with males being slightly more affected than females (M/F=1.18). The mean survival 
time after tumor removal ranges between 6 to 8 years but the survival time chiefly depends on its eventual 
progression to glioblastoma multiforme, normally occurring after 4-5 years (Louis et al., 2007). 
Anaplastic astrocytoma (AA) typically affects adults (45 – 55 years of age) and is preferentially 
located in the cerebral hemispheres. AA is considered an intermediate glioma subtype assigned between 
DA and glioblastoma multiforme since after approximately 2 years of its diagnosis it tends to progress to 
glioblastoma multiforme (secondarily). However, AA is also recorded to arise without previous history of 
a less malignant tumor (primarily). Males are more affected than females (M/F=1.31) and older patients 
have shorter survival times (Louis et al., 2007). 
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 Glioblastoma multiforme (GBM) is the most frequent glioma subtype (~90%), most commonly 
affecting people between 45 and 75 years of age (Louis et al., 2007). It preferentially develops in deep 
white matter regions (Tatard et al., 2010) and is characterized by large histological/molecular 
heterogeneity (Louis et al., 2007). GBM can arise primarily, without previous history of brain tumor, or 
secondarily, progressing from lower grade glioma subtypes (DA and AA). Some evidence indicates that 
anaplastic oligodendroglioma might also be a precursor to GBM (DeAngelis, 2009). Approximately 
9,000 new cases are estimated to occur in the United States per year with males being predominantly 
more affected than females (M/F=1.26). GBM is considered a very aggressive cancer and due to its 
invasive nature cannot be completely removed by surgery. The survival rate for newly diagnosed patients 
is estimated as 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years, but older patients tend to have 
even worse prognoses (Louis et al., 2007). 
Oligodendroglioma (O) typically affects adults (40 – 45 years of age) and preferentially arises in 
the cerebral hemispheres. Approximately 5-6% of gliomas are classified as O and tumors of this type 
frequently present chromosomal deletions in the arms 1p and 19q. Males are slightly more affected than 
females (M/F=1.1). Estimates show that in the United States close to 50% of patients survive 10 years 
after diagnosis and surgical resection (Louis et al., 2007). 
Anaplastic oligodendroglioma (AO) is reported mainly in adults between 45 and 50 years of age. 
AO preferentially develops in the frontal lobe and can arise primarily or secondarily (from O) tumors. 
Approximately 1.2% of the PBT are classified as AO with males being slightly more affected than 
females (M/F=1.1). Median survival time estimates are quite variable ranging from 1 to 4 years 
depending on the studied population (Louis et al., 2007). 
Oligoastrocytoma (OA) mainly affects adults between 35 to 45 years of age with annual 
incidence estimated as 1 case per million population. However, reported incidence has increased over the 
last decade, probably due to improvements in histological recognition techniques. Males are more 
affected than females (M/F=1.3) and the median survival time is reported to be around 6 years (Louis et 
al., 2007). 
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Anaplastic oligoastrocytoma (AOA) accounts for 1-4% of all gliomas and affects patients with 
median age of 44 years. It is still uncertain if AOA arises only primarily or also secondarily from OA. 
Males are more affected than females (M/F=1.15) and the median survival time of AOA patients is 
estimated as 2.8 years (Louis et al., 2007). 
 Imaging techniques, as magnetic resonance imaging, are noninvasive techniques currently used 
by clinicians to first diagnoses and assess the glioma and characterize its surrounding tissues (Diehn et al., 
2008). Following tumor resection, a biopsy is performed and the diagnosis is confirmed by histological 
examination (Castells et al., 2009). However, some authors suggest that histopathological classification 
might be inaccurate sometimes (Castells et al., 2009; Nutt et al., 2003). For example, even though 
primary and secondary gliomas are considered distinct diseases, they share histological similarities and 
are distinguishable only if a lower grade lesion is previously recorded. The classification is, therefore, 
subject to error in situations where secondary gliomas rapidly arise and progress (Nobusawa et al., 2009). 
Histopathological classification is also strongly susceptible to inter-observer variability and is not easily 
reproducible (Gravendeel et al., 2009; Nutt et al., 2003). Coons et al. (1997) and Giannini et al. (2001) 
show that the concordance in diagnosis based on histological features can range from only 5% to a 
maximum of 80% among experienced neuropathologists and neurosurgeons. Since the following 
treatment decisions and therapy response predictions are based on the glioma subtype, a more objective 
and accurate method of glioma classification is urgently needed (Nutt et al., 2003). 
 Lately, immunohistochemical markers have been used for classification of gliomas. Examples are 
the GFAP (glial fibrillary acidic protein) which is always present in astrocytomas but seldom in 
oligodendrogliomas, and OLIG2 (oligodendrocyte transcription factor 2), a specific oligodendroglioma 
marker (Furnari et al., 2007). Recent research efforts indicate that molecular profiling of gliomas is also a 
promising tool for tumor classification and consequently for better outcome prediction (Hayden, 2010). 
For instance, losses on chromosomes 1p and 19q as well as mutations in CDKN2A, IDH1 and TP53 
might be associated with a poor prognosis for oligodendroglioma (O and AO) patients (Cairncross et al., 
1998). Also, distinct patterns of gains and losses of chromosomal regions can distinguish primary (EGFR 
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amplification) and secondary (TP53 mutation) GBM lesions (Maher et al., 2006). In addition, Phillips et 
al. (2006) and Verhaak et al. (2010) identify three to four GBM subtypes, namely Proneural, Neural, 
Classical (Proliferative), and Mesenchymal, based on the analysis of microarray expression of signature 
genes suggesting that high-grade gliomas are associated with the over-expression of “stem cell” genes 
(proliferative/mesenchymal phenotype) while low-grade gliomas have higher expression of neuronal 
genes (well-differentiated phenotype). 
 
1.2. Molecular alterations in gliomas 
 The most common genetic alterations in gliomas occur in biological processes directly involved 
in cell proliferation, apoptosis, necrosis, angiogenesis, and invasion (Furnari et al., 2007). The RB 
(retinoblastoma) and p53 pathways are usually found altered in gliomas (Furnari et al., 2007; TCGA, 
2008) and are directly associated with cell cycle regulation via the control of mitogenic factors such as 
MAPK (mitogen-activated protein kinase) and RTK (receptor tyrosine kinase). RB controls cell 
proliferation by inactivating mitogenic factors of the MAPK cascade which induces the formation of 
cyclins and their associations with CDK (cyclin-dependent kinase) complexes. Some PI3K 
(phosphoinositide 3-kinase) family members are important pieces of the RTK pathway and have been 
reported to have their expression altered in gliomas (Kang et al., 2006). Similarly, the p53 transcription 
factor regulates the promoters of thousands of genes, among them many CDK complexes, and is best 
known for its role in activating apoptosis and consequently tumor suppression. Not only TP53 mutations 
are commonly found in gliomas but also two of its key negative regulators – MDM4 (Mdm2-like p53-
binding protein) and CHD5 (Chromodomain-helicase-DNA-binding protein 5) – have their expression 
frequently altered. In addition, PTEN (phosphatase and tensin homolog), one important tumor suppressor 
regulated by p53, is also downregulated in 50% of gliomas (Ohgaki et al., 2004). In approximately 40% 
of GBM samples, the abnormal activation of the cell proliferation pathway might be explained by the 
overexpression of the EGFR (epidermal growth factor receptor) gene, a membrane receptor. 
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 In addition to the p53 network, another group of molecules called the “death-receptors” are 
particularly involved in the control of apoptosis. The “death receptors” are membrane receptors such as 
TNRF1 (tumor necrosis factor receptor 1), TRAIL R1 (TNF-related apoptosis-inducing ligand receptor 
1), TRAIL R2 (TNF-related apoptosis-inducing ligand receptor 2), and FAS (TNF receptor superfamily, 
member 6), which are linked to the activation of caspases and have been reported altered in gliomas 
(Furnari et al., 2007). Likewise, members of the Bcl-2 (B-cell CLL/lymphoma 2) family are frequently 
altered in gliomas (Furnari et al., 2007). Bcl-2 family members are known by their roles in modulating 
cell death (pro-apoptotic or anti-apoptotic roles), through caspase pathway activation, and by initiating 
migration and invasion processes in glioma cells (Wick et al., 2004). It is suggested that 
apoptotic/necrotic pathways are, at some degree, interconnected, which is corroborated by the discovery 
of the protein Bcl2L12 which shares homologies with members of the Bcl-2 family and has the ability to 
deactivate caspases, hence switching apoptosis to necrosis in gliomas (Nicotera & Melino, 2004). 
 Angiogenesis, microvascular proliferation of endothelial cells (Stiver et al., 2004), is a marked 
characteristic of both primary and secondary GBM and is one of the many histological features used to 
identify distinct subtypes of gliomas. The underlying molecular mechanisms of angiogenesis involve 
many different regulators (especially VEGF, PDGF, IL-8, thrombospondins, endostatin, and interferons) 
of the hypoxia-induced factor (HIF) pathway (Nyberg et al., 2005) and it has been shown that many 
common mutations found in gliomas — PTEN, EGFR, and CMYC genes — modulate angiogenesis via 
the HIF pathway (Shchors et al., 2006). Likewise, underlying biochemical processes of cell invasion — 
another hallmark of gliomas — have similarities with the development of SNC (Furnari et al., 2007). 
Many genes involved in cell invasion regulation have already been reported altered in gliomas, including 
members of the family of metalloproteases (Wang et al., 2003a), urokinase-type plasminogen activator 
(Landau et al., 1994), cysteine proteases (McCormick, 1993), IGFBP2 (Wang et al., 2003b), ephrins, and 
P311 (Furnari et al., 2007). 
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1.3. Treatment and prognosis 
 Applying therapy to glioma patients is still a challenging task since the majority of patients 
experience undesirable side effects (Furnari et al. 2007) and show little improvement after neurosurgery, 
chemotherapy, and radiotherapy (Freije et al., 2004). Two factors are believed to contribute to the poor 
prognosis (Cairncross et al., 1998). First, gliomas present remarkable molecular heterogeneity, and 
consequently therapies targeting a specific pathway attain survival improvement for only a small fraction 
of the patients. Second, the hemato-encephalic barrier provides tumor cells with the ability to evade 
chemotherapy and the invasive nature of gliomas makes complete tumor resection almost impossible. In 
spite of these difficulties, some good results have been obtained in recent years. A third of the 
oligodendroglioma (O and AO) patients have been shown to be particularly sensitive to combined 
treatment with procarbazine, lomustine, and vincristine (PCV) due to mutations on chromosomes 1p and 
19q (Cairncross et al., 1998). Mixed gliomas (OA and AOA) have also been reported to have a substantial 
improvement in prognosis after PCV therapy (Cairncross et al., 1998). In addition, glioma patients with 
unmethylated MGMT promoters become more sensitive to alkylating agents and respond positively to 
temozolomide treatment (DeAngelis, 2009; Hegi et al., 2005; TCGA, 2008). Freije et al. (2004) also 
report some improvement in a small group of patients treated with irinotecan. 
 Currently, prognosis is basically based on tumor grading/subtypes and patient age (Furnari et al., 
2007). However, the molecular heterogeneity of gliomas along with the variability in response to therapy 
highlight the importance of cataloging and discovering the intricate genome alterations in glioma tumors 
which, consequently, will improve prognosis and bring new perspectives of therapy for this disease in the 
field of small molecule drugs, therapeutic antibodies or RNA interference based factors (Freije et al., 
2004). Further, increasing the sample size and using adequate methods to handle peculiarities of 
molecular data can, in fact, improve survival prediction of glioma patients and better guide disease 
management. 
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1.4. Survival prediction using DNA microarray data 
 During the past few years, a new promising avenue in genomics and molecular biology became 
available. Microarray data can provide information about thousands of genes simultaneously and, 
therefore, provide a complete picture of the functioning of whole genomes and, consequently, generate 
alternatives for cancer treatment (Gentleman et al., 2005). Gene expression profiling using DNA 
microarray technology has successfully identified molecular subtypes of cancer and revealed associations 
of gene expression patterns with disease recurrence and survival prognosis of patients (Alizadeh et al., 
2000; Berchuck et al., 2005; Garber et al., 2001; Sorlie et al., 2001; Yeoh et al., 2002). Survival 
prediction is often formulated in terms of categorical outcomes (e.g. ‘poor’ vs. ‘good’ prognosis) which 
might be useful for guiding decisions about cancer management and treatment (Ross, 2009). However, 
due to a large heterogeneity observed within prognostic classes, prediction of time to a clinical 
event/occurrence can be poor. Improvement of survival prediction accuracy can be attained by relating 
time-to-event to gene expression profiles directly. This requires specific survival analysis methods to 
account for the presence of censored outcomes, such as the (multivariable) Cox proportional hazards 
(CPH) model (Cox, 1972) and the accelerated failure-time model (AFT) (Klein & Moeschberger, 1997). 
 In spite of their wide use in other settings, these standard multivariable survival methods cannot 
be directly applied to clinical outcome prediction using gene expression data since the number of 
covariates (genes) under investigation is considerably larger than the number of samples (patients) -- this 
is called the “large p, small n problem" (West, 2003). Many different strategies have been employed to 
solve this high dimensionality problem. For example, clustering techniques have been applied for 
grouping correlated sets of genes; the average expression level of each cluster is then used as a covariate 
(metagene) in the survival model (D'haeseleer, 2005). Likewise, linear combinations of covariates 
obtained by partial least squares (Nguyen & Rocke, 2002; Park et al., 2002) or the principal components 
of the design matrix (Li & Gui, 2004) have been used as explanatory variables in survival regression 
models. In addition, some authors propose the use of penalized versions of the CPH model, L1-penalized 
(Lasso regression) and L2-penalized (ridge regression), for estimating parameters while simultaneously 
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performing variable selection (Gui & Li, 2005; Park et al., 2002; Tibshirani, 1997; Zou & Hastie, 2005). 
Similarly, Huang et al. (2006) and Datta et al. (2007) developed penalized variants of the AFT model for 
fitting models in high-dimensional data settings. Bayesian techniques for variable selection have also 
been developed for Weibull and CPH models (Lee & Mallick, 2003) as well as the AFT model (Sha et al., 
2006). 
 While these strategies address the high-dimensionality problem with some degree of success, they 
fail to incorporate complex interactions between genes, since the genes are modeled in an additive and 
linear manner. Ensemble methods like bagging (Breiman, 1996), boosting (Friedman, 2001), and random 
forests (Breiman, 2001) are very flexible alternatives for accommodating variable interactions and are 
notably more stable in high-dimensional settings (Breiman, 1996, 2001). Tree ensemble methods are 
based on a recursive partitioning strategy, where a tree is built by successively splitting the observations 
into binary nodes. If  denotes the splitting covariate, one node contains all observations with    , 
while the other node contains all observations with    . The covariate  and the threshold  are 
selected based on a splitting criterion and the growing or pruning of trees is based on a stopping criterion 
(see details in the following sections). 
 Because ensemble methods use a linear combination of trees to fit data variation where each tree 
fits part of the data, these methods have been shown to have high predictive accuracy (Lee et al., 2005). 
These ensemble methods were originally developed for modeling binary or continuous responses. 
Extensions for modeling survival data, often called survival ensembles (Hothorn et al., 2006), address the 
censoring problem by growing relative risk forests (Ishwaran et al., 2004), by imputing censored 
observations (Ishwaran et al., 2008), or by using a Kaplan-Meier curve aggregation procedure to predict 
survival of a new observation (Hothorn et al., 2004). In general, survival ensemble methods estimate a 
survival function for each terminal node of the tree, weighing censored observations differently and then, 
prediction is performed by dropping down the tree a new observation (Hothorn et al., 2006). A different 
approach proposed by Schmid & Hothorn (2008) estimates both the predictor function of the AFT model 
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and simultaneously the scale parameter, so that a boosting algorithm can be applied to minimize a pre-
defined loss function. Even though Bayesian estimation has been shown to improve the predictive 
performance of tree models with nominal or continuous responses (Chipman et al., 1998; Denison et al., 
1998; Pittman et al., 2004), Bayesian survival ensembles are still limited to the study of Clarke & West 
(2008) who proposes tree-based Weibull models for outcome prediction of advanced stage ovarian 
cancer.  
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2. Objectives 
 
 The hypothesis of this research is that molecular profiling of brain tumors coupled with clinical 
information might better predict patient survival time. In addition, we hypothesize that the use of survival 
methods which incorporate interactions and work well in high-dimensional settings can improve 
prediction accuracy for survival times. We evaluate these hypotheses by building models for survival 
prediction of glioma patients (section 3.1).  
 First, a predictive Random Forest model is built for binary outcomes (i.e. short vs. long-term 
survival) and a small subset of genes whose expression values can be used to predict survival time is 
selected (section 3.2). Random Forest predictive accuracy along with a list of the most important genes 
used for prediction are shown in section 4.1. Following, a new statistical methodology is developed for 
predicting time-to-death outcomes using Bayesian ensemble trees. Due to the large heterogeneity 
observed within prognostic classes obtained by the Random Forest model, prediction can be improved by 
relating time-to-death outcomes to the gene expression profiles directly. The new approach is based on 
the ensemble “sum-of-trees" model (Chipman et al., 2006) and hence is defined by a likelihood and a 
prior. A fully Bayesian hierarchical approach is specified with uncertainty in estimation being propagated 
at each stage of hierarchy to make predictions. The new methodology is illustrated using three popular 
survival models - CPH (section 3.3.1), Weibull (section 3.3.2), and AFT models (section 3.3.3). The new 
approach is unique as it overcomes the lack of conjugacy using a latent variable formulation to model the 
covariate effects and, as a result, model fitting becomes efficient and computationally less expensive 
(section 3.3.4). The new approach is non-parametric and incorporates additive and interaction effects 
between genes which results in high predictive accuracy as compared to other methods. In addition, it 
provides a model-free way to select important predictive prognostic markers based on controlling false 
discovery rates (section 3.5). The predictive accuracy of the new method is compared (section 4.2) with 
baseline reference survival methods reviewed by van Wieringen et al. (2009) using the breast cancer data 
set of Van't Veer et al. (2002). The results of the new methodology applied to the brain tumor data set are 
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presented in section 4.3. A closing discussion compares results obtained by Random Forest and Bayesian 
ensemble methods under the biological/clinical perspectives and stresses the statistical advantages and 
disadvantages of the new methodology in the context of DNA microarray data analysis (section 5). 
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3. Methods 
3.1. The data set 
 A set of gene expression profiles for brain tumor patients is used here to identify molecular and 
genetic signatures which could be of prognostic value. The data set contains gene expression 
measurements, patient age, tumor grade, and survival information for 734 patients obtained from nine 
different cancer treatment institutions (Table 1). 
 The survival time after diagnosis ranges from 1 to 698 weeks with 15% of the observations being 
censored (Figure 1). Survival time was discretized into short-term survival (STS ≤ 24 months — 70% of 
patients) vs. long-term survival (LTS > 24 months — 30% of patients) before using the Random Forest 
classification method. Gene expression values of 11,911 genes are obtained using three different 
Affymetrix microarray chips (142 from HT-U133A, 355 from U133A, 237 from U133Plus2 -- Figure 2 
and Table 1). The annotation was reformulated using a customized CDF file organized by the BrainArray 
Group, Department of Psychiatry, University of Michigan (see more details in Dai et al., 2005 and at the 
group's website: brainarray.mbni.med.umich.edu/). The data was pre-processed using Batch 
normalization available in the JMP Genomics SAS® software and then quantile normalization (affy 
package in R) in order to account for batch effects. The data have not been made publicly available by the 
time when this thesis was written but, upon request, the data can be obtained from Dr. Erik P. Sulman 
(Department of Radiation Oncology, MD Anderson Cancer Center).   
 Instead of the original set of 11,911 genes, we work with a reduced set of 142 metagenes which 
are obtained by applying an unsupervised clustering algorithm, Gene Shaving (Do et al., 2003; Hastie et 
al., 2001). Gene Shaving identifies the largest principal component, clusters the genes highly correlated 
with it and shaves out the less correlated ones. Then the following largest principal component is found 
and the procedure repeats until around 85% of the genes were shaved out. The metagenes are then 
constructed from the clusters as signed average of its members. As a result, 1,623 genes were selected and 
grouped in 142 metagenes ranging in sizes from 2 to 87 genes (Figure 3). 
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 Even though the methods treated here are capable of handling this high-dimensional setting 
(11,911 x 734), we decide to work with a lower dimensional data set (144 x 734) to be able to compare 
our results with multivariable versions of the linear competing methods using the same set of predictors. 
In addition to the 142 metagenes, clinical covariates such as patient age and histopathological tumor grade 
(II, III, or IV) were also added as covariates in the survival model. For the survival ensemble methods, a 
cross-validation procedure was performed with the data being randomly split 10 times into training and 
test sets with a 2:1 ratio. We first build the predictor using the training set and then assess and compare 
the performance of different methods using evaluation measures calculated for the test set. 
 
 
Figure 1: Kaplan-Meier survival curve (solid line) for all 734 glioma patients along with the 95% 
confidence interval (dashed lines). Plus signs indicate right-censored observations. Horizontal axis shows 
the natural log of survival times in weeks. 
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Figure 2: Heatmap of the top 2,000 genes selected by a t-test comparing averages of expression values 
for STS and LTS groups of glioma patients. Green color spots represent under-expressed values and red 
color spots represent over-expressed values. Samples are depicted in the horizontal axis and genes in the 
vertical axis. Dendrograms were obtained by "Ward" method. Blue labels at the top of the figure indicate 
STS patients while yellow labels indicate LTS patients. 
 Figure 3: Distribution of sizes of the 142 metagenes obtained by Gene
  
16 
-Shaving. 
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Table 1. Cancer center providers and distributions of array types and survival times of glioma samples. 
Institution Total of 
samples 
Array Type Survival 
HT-U133A U133A U133Plus2 STS LTS 
UCLA 166 0 157 9 130 36 
MDA 145 32 75 38 74 71 
TCGA 110 110 0 0 97 13 
Henry Ford 104 0 0 104 58 46 
EORTC 65 0 0 65 54 11 
Collins 61 0 61 0 46 15 
UCSF 31 0 31 0 24 7 
Duke 31 0 31 0 28 3 
Belgium 21 0 0 21 3 18 
Total 734 142 355 237 514 220 
 
3.2. Random Forest 
 Random Forest (RF) is an ensemble tree-based method which is appropriate for classification of 
DNA microarray data because it handles high-dimensionality well, it is able to perform model-free 
variable selection, and it is flexible enough to incorporate interactions between genes, which confers on it 
a highly predictive accuracy when compared to alternatives (Diaz-Uriarte & Alvarez de Andres, 2006). 
The Random Forest (RF) model is based on a collection of individual tree-structured predictors 
	
, , where 
 is the data and  represents a subset of randomly selected covariates chosen with 
replacement to build the trees (Breiman, 2001). Each tree votes for the most popular class at input  and 
the size of  has to be set a priori. If  is set equal to the total number  of covariates the bagging 
algorithm is obtained (Breiman, 1996). RF is applicable for classification or regression and does not 
assume any particular stochastic model. The prediction error within sample converges to a limit as the 
number of trees increases (Breiman, 2001). Trees are grown as large as possible and are not pruned as in 
other tree-based methods. A bootstrap sample of samples from the original data set is used to build each 
tree in the forest and the samples not sampled are referred to as out-of-bag (OOB) observations. OOB 
prediction is obtained by the majority of the votes involving only those trees that did not contain the 
corresponding sample. The frequency that a covariate is used to build the trees defines a measure of 
variable importance which is used here for feature selection (Shi & Horvath, 2006). 
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3.3. Survival ensembles 
 We denote the observed data for the   patient 	  1, … ,  as , the survival time, along with 
, the event indicator function, where   0 if data is right censored and   1 if it is not. In addition to 
the survival response, the -dimensional vector of covariates (genes/probes) potentially associated with 
the   patient survival time, X, is also available. Let   	, … ,  denote the vector of survival times 
and let X (samples by metagenes) denote the matrix of gene expression data. In the following, we 
develop survival distribution models which aids to predict the survival time of a new patient with 
covariates X !. 
 Modeling of survival data usually proceeds in two steps: (1) specification of a sampling 
distribution p	|#	
, conditional on a function of the covariates #	
, such as modeling either the 
hazard function (as in CPH models) or the survival time directly (as in Weibull and AFT models) and (2) 
the regression function #	
 which models the covariate effects. Usually, for computational convenience 
it is assumed that the covariates are linearly and independently related to survival, such that #	
  ′$ 
where $ is a vector of  unknown regression coefficients that captures the covariate effects on survival 
time or hazard. There are two drawbacks of this approach. First the linear and independent assumption is 
a restrictive one. Second, and more importantly, in high throughput studies such as gene expression data 
the problem becomes much more complex when , the dimension of 
, is very large, possibly larger than 
the sample size . This makes the estimation of $ unstable and the high-dimensionality problem is 
exacerbated if interactions between covariates are considered. Dimension reduction approaches such as 
feature selection or partial least squares alleviate the problem to a certain degree. However, these methods 
are based on linear relationships between the response and the covariate which may not be very realistic. 
If the actual # is nonlinear, these models may fail to produce reasonable prediction due to lack of 
flexibility. We propose to model #	
 in a flexible manner using ensemble methods that not only 
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accommodate nonlinear effects but also incorporates interactions of covariates to estimate the effects on 
survival time as we describe below. 
 
3.3.1 Ensemble-based Proportional Hazards Regression 
 The proportional hazards model (Cox, 1972) is one of the most popular survival models in the 
statistical literature. Rather than modeling time-to-event directly, it models the hazard function %	, at 
any time  as 
 
%	|&  %'	(&	), 
 
where %'	 is the baseline hazard function and ) is an unknown function modeling the associated latent 
covariate effect. The joint conditional survival function of  in the CPH model can then be written as 
 
*	|), +  (&,- ∑ +	/ (&	)0, 
 
where + represents the cumulative hazard function. The associated complicated form of the likelihood 
makes it impossible to express conditional distributions of the parameters 	), + in closed forms (Ibrahim 
et al., 2001). As a result, the drawing of posterior distributions requires the sampling of all model 
parameters using complex MCMC procedures at each iteration, making the process computationally 
intensive with potential poor mixing, especially in high-dimensional settings. 
  We simplify the joint likelihood in two ways. First, for the cumulative hazard function we follow 
the approach in Kalbfleisch (1978) by specifying a Gamma process prior for +, such that 
 
+ ~23	4+5, 4, 
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where +5 is the mean process and 4 is a weight parameter about the mean with  
+	~64774	4+5	, 4. The utility of using the Gamma process prior is that the + vector can be 
analytically integrated out such that the marginal likelihood conditional on ) can be written as 
 
L	|)   exp <- = aW+5	
@
/
A B	aC5	WDE
@
/
, 
 
where  is the indicator for event, F  ∑ exp	)G@HIJ	KL ,   1, … , , R	t is the set of individuals at 
risk at time t, and O  1 - exp	) 	a P F⁄ . 
 Second, we modify the model by treating the ) 's as random latent variables, conditional on 
which the t's are independent of X 's by the following factorization: p	t|)p	)|X. This latent 
variable feature allows us to elicit conjugate priors for ) 's, making the sampling from full conditionals 
fast and more efficient. Specifically, we assume a Gaussian process on p	)|X, such that )  #	X P
R, where #	X is the regression function and R are residual random effects assumed to be distributed 
STU74	0, VW. The residual random effects R accounts for the unexplained sources of variation in the 
data, most probably due to explanatory variables (genes) not included in the study (Lee & Mallick, 2003). 
 Therefore, the full conditional of the Ensemble-based Proportional Hazards regression is written 
as 
p	)|+,X,VW, ,  X  exp <- = aW+5	
@
/
A B	aC5	WDE
@
/
 exp Y- 12VW ,) - #	X0′[,) - #	X0\ 
log,p	)|+,X,VW, , 0 X  - ∑ aW+5	@/ P  d ∑ log	aC5	W@/ P MVN	#	X, VW[, 
 
and the joint posterior survival function defined as 
 
*	|)  d eefghi 	jkel
5
, 
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 We approximate #	· using a tree-based ensemble method to model not only the non-linear 
effects of the genes but also account for the high-dimensionality of the data. We use the "sum-of-trees" 
approach of Chipman et al. (2006) (CGM, henceforth) called the Bayesian Additive Regression Trees 
(BART) model as our candidate choice due to its excellent predictive performance on a variety of data 
sets. Compared to other ensemble methods, BART is also preferable because it is explicitly defined in 
terms of a full probability model, i.e. with likelihood and priors, and, therefore, a full Bayesian 
hierarchical approach can be implemented for estimation of all relevant uncertainties. We present a brief 
review of BART below and refer to CGM for more details. 
 Let T represent a single decision tree containing both internal and terminal nodes. Internal nodes 
of the tree are grown through recursive partitions of the data using splitting rules. Splitting rules produce 
binary splits of the data and are defined in terms of splitting variables and cutoff values. Dropping an 
individual with covariates x down the tree assigns it to a terminal node according to the tree splitting 
rules. Let each tree be indexed by B terminal nodes and define µ=	m, … , mn as the vector of averages mo 
of individuals assigned to the same node b, where b = 1,…,B. So each observation can be mapped by a 
function # such that #	x  p	x , q,µ. 
 Since BART is a "sum-of-trees" model # can be approximated by 
 
#	
  ∑ p	
, qr, srtr/ , 
 
where u is the total number of trees. Compared to single tree models, BART is more flexible since 
several trees incorporate the additive effects and, consequently, improve estimation. 
 We note that the number of regression trees u set for the tree-ensemble methods dictates how 
often a covariate will be selected to be part of the model. CGM show that setting a relatively small 
number of trees benefits the variable selection procedure since variables compete with each other to 
improve fit and therefore, relevant predictors should appear more frequently in the tree model. Because 
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we are interested in exploring the BART variable selection feature, we performed a previous study 
examining the trade-off between total number of trees and computational time and found out that setting 
u  40 is a feasible number for all survival ensemble methods described in this section (Figure 4). 
 To complete the full Bayesian hierarchical formulation of our ensemble-based proportional 
hazard regression model we need to specify the following priors: p	)|#	
, VW, p	VW|w, and p	#|w 
where w  	T, m, … , Ty, mr represents the tree-specific parameters. Our prior for p	# is of the form, 
 
p	#  ∏ p	qy, sr{y/  ∏ p	qyp	sr|qy{y/ , 
 
where the second equality is obtained by recursively conditioning on the terminal nodes. 
  We follow CGM and define p	qy by three factors: (i) the distribution on the splitting variable 
assignments at each interior node is a uniform prior over all available variables, (ii) the distribution on the 
splitting rule assignment in each interior node, conditional on splitting variable is a uniform distribution 
over the set of available splitting values, and (iii) the probability that a node at depth | is nonterminal is 
given by }	1 P  d~g, where } I 	0, 1 and ( I 	0, ∞ are fixed parameters controlling the size of the 
tree. Following CGM we set }  0.95 and (  2 to give prior probabilities of 
	0.05, 0.55, 0.28, 0.09, 0.03 for trees to have 	1, 2, 3, 4,  5 terminal nodes, respectively. As in CGM 
we assume i.i.d conjugate normal priors for p	sr|qy. Assigning prior distributions for the set of tree 
parameters q and s constrains the sizes of the trees avoiding the model being populated by non-
informative covariates. This imposed variation in tree sizes grants BART flexibility for accommodating 
main effects as well as their interactions of different orders (more than one splitting rule) which results in 
a better predictive performance obtained by BART when compared to competing methods such as 
random forest and boosting algorithms. To complete the prior formulations we assume a conjugate 
inverse chi-square distribution on VW as VW~  W⁄ , with  being a data-determined fixed 
hyperparameter. 
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 Concisely, the complete hierarchical Bayesian model for ensemble-based CPH model can be 
written as, 
 
|) ~ 	|), 
)|#	X, VW ~ STU74	#	X, VW, 
#	X ~ U((	w, 
VW ~  W. 
 
3.3.2. Ensemble-based Weibull Regression 
 The Weibull model is a parametric model used extensively in describing lifetimes and can be 
reparameterized both as a CPH as well as an AFT model (Klein & Moeschberger, 1997). The Weibull 
distribution is indexed by a shape parameter τ and scale parameter ψ and it models the probability of 
survival at time t for patient i as, 
 
#	|τ, ψ  τψ(&,-ψτ0[	E;τ;ψL. 
 
 Reparameterizing the scale parameters as )  log,ψ0 the Weibull likelihood can be written as, 
 
#	|τ, )  ττ~(&,) - (&	)τ0[	E;τ, 
 
and the survival function as *	|τ, )  (&	-(&	)τ. Letting ∆  ∑  represent the number of 
censored observations, the joint likelihood function for the parameter τ and the vector of parameters 
   	), … , ) becomes 
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L	τ, |
, , δ   B #	|τ, )DE*	|τ, )~DE
@
/
 
L	τ, |
, , δ   	τ∑ DE	∑ DE	τ~(& <=	)
@
/
- = (&	)τ
@
/
- =	1 - (&	)τ
@
/
A 
L	τ, |
, , δ   τ∆	∑ DE	τ~(& <=	)
@
/
- = (&	)τ
@
/
A 
L	τ, |
, , δ   τ∆(& <=	)
@
/
P = 	τ - 1Tp	
@
/
- = (&	)τ
@
/
A 
L	τ, |
, , δ   τ∆(&,∑ ,) P  	τ - 1Tp	0@/ - ∑ (&	)τ@/ 0. 
 
 For convenience, we let   log	τ and write the conditional distribution of the vector  as 
 
p	|
, , δ,  X  (& <∆ P = d) P  ,e - 10Tp	k
@
/
- = (&	)g
@
/
A 
 exp - W ,) - #	X0′[,) - #	X0. 
 
 Since )'s are conditionally independent, we conveniently draw their posterior distributions 
componentwise from 
  
p	)|)H, 
, , δ,  X  (& d∆ P ) P  ,e - 10Tp	 - (&	)gk 
 exp d- W ,) - #	0Wk. 
 
  Following, we also use Metropolis-Hastings to draw the conditional of  from 
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p	|, 
, , δ X  (& <∆ P = d) P  ,e - 10Tp	k
@
/
- = (&	)g
@
/
A  e	τ~e~ge. 
 
 As in the previous section, we model the covariate effects ) 's as latent variables as 
STU74	#	X, VW, with # being modeled using BART. We complete our hierarchical model assigning 
a conjugate gamma prior on τ as 64774	τ, k, with fixed but vague hyperparameters. Thus our 
ensemble-based Weibull regression model can be written as, 
 
|τ, ) ~ O(¡¢	τ, ), 
τ ~ 64774	τ, k, 
)|#	X, VW ~ STU74	#	X, VW, 
#	X ~ U((	w, 
VW ~  W. 
 
3.3.3. Ensemble-based Accelerated Failure Time Model 
 The AFT model is a parametric survival model that assumes that the individual survival time  
depends on the multiplicative effect of an unknown function of covariates #	X over a baseline survival 
time £. The AFT model (on log-scale) can be written as, 
 
log	   £ P #	X P R,   1, … ,  
 
where # captures the covariate effects affecting the (log) survival time directly. 
 We assume the random errors R 's are normally distributed, however other distributions such as 
extreme-value or t distribution (Klein & Moeschberger, 1997) can easily be adopted. Note that under an 
extreme-value distribution, the AFT model is equivalent to the Weibull model described previously. 
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 As before, let ) be a latent variable such that )  #	X P R, where R 's are i.i.d 
STU74	0, VW. The AFT model can now be expressed as 
 
¤log	5   £ P #	X, if         1,         log	5   £ P #	X         if         0,¦ 
 
where £ is assigned a conjugate normal prior distribution as STU74	£', £§, where £' and £§ are fixed 
hyperparameters. 
 After estimating ), we define U  log	5 - ) where U|£, VW ~ STU74	£, VW. Now, we 
specify a conjugate prior for £ as £|£', £§ ~ STU74	£', £§, which makes the posterior distribution 
of £|U, VW, £', £§ be an updated STU74	£5, V5, where £5  ¨©f¨ª ∑ «Ef¨ª  and V5  ¬ ¨ªf¨ª. 
Therefore, the censored survival times (  0) are sampled from univariable normal distributions 
STU74	£ P ), VW truncated at log	5. 
 Thus our ensemble-based AFT model can be succinctly written as, 
 
|£, ) ~ STU74	£ P ), VW, 
£|£', £§ ~ STU74	£', £§, 
)|#	X, VW ~ STU74	#	X, VW, 
#	X ~ U((	w, 
VW ~  W. 
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Figure 4: Size of trees. Figure shows the Brier Score for the test data depending on the number of trees 
set for the BART model. Left plot - AFT-TREE; center - WEI-TREE; Right - CPH-TREE. Each line 
represents one training/test split of data. 
 
3.3.4. Model fitting via MCMC 
 We use Markov Chain Monte Carlo (MCMC, Gilks et al., 1996) algorithms to generate samples 
from our posterior distributions. The specific drawing scheme for the CPH model uses a Gibbs sampler to 
estimate the set of parameters 	, w, VW. The Gibbs sampling method iterates ­  1, … , ® times through 
the following steps: 
 (1) Update w using the Bayesian backfitting MCMC algorithm described in CGM; 
 (2) Update VW|w using a Gibbs sampler; 
 (3) Update )|w, VW, where   1, … , , using for each ) a Metropolis-Hastings procedure 
with a proposal density q	), )5 which generates moves from the current state ) to a new state )5. 
The probability of accepting the change is given by 
 
°jE  7 d1, i	jE5|j±²E,X,t³	jE5,jEi	jE|j±²E,X,t³	jE,jE5 k. 
 
 The posterior distributions of the Weibull model parameters 	, w, τ, VW are obtained in a similar 
manner: 
 (1) Update w using the Bayesian backfitting MCMC algorithm described in CGM; 
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 (2) Update VW|w using a Gibbs sampler; 
 (3) Update )|w, τ, VW componentwise, where   1, … , , using for each ) a similar 
Metropolis-Hastings procedure with probability of accepting the change given by 
 
°jE  7 d1, i	jE5|j±²E,X,t,δ,τ³	jE5,jEi	jE|j±²E,X,t,δ,τ³	jE,jE5 k. 
 
 (4) Update τ|, w, VW also using the Metropolis-Hastings procedure with acceptance probability 
 
°τ  7 d1, i	τ5|,w,t,δ³	τ5,τi	τ|,w,t,δ³	τ,τ5 k. 
 
 The drawing scheme for the AFT model parameters 	, £, VW follows these steps: 
 (1) Update w using the Bayesian backfitting MCMC algorithm described in CGM; 
 (2) Update VW|w using a Gibbs sampler; 
 (3) Obtain £|w, VW, ; 
 (4) Update ) if   1; 
 (5) Sample from a STU74	£ P ), VW truncated at  if   0. 
 
3.3.5. FDR-based Variable Selection for Ensemble Models 
 As mentioned before, BART offers a model-free mechanism to do variable selection. Let p, ´0 
denote the posterior probability inclusion of gene µ´ in the model, ¶  1, … , . We approximate p, ´0 
based on the relative frequency of occurrence T·of the  covariate across ­ MCMC samples as 
 
p, ´0 ¸ ¹ ∑ T·¹/ , 
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where T· is the indicator function I, µ´ I 
0, where 
 is the set of covariates used to the build the tree 
model in the ­ MCMC iteration. 
 We consider any covariate µ´ with p	´ º », for some threshold », as significantly used (true 
discovery) in the model. The significance threshold » can be set to control the average Bayesian FDR 
(Morris et al., 2008) and it is thus a Bayesian q-value (Storey, 2003). In our study, we are interested in 
finding the value »¼ that controls the overall FDR at the level ½, meaning that we expect only 100½% of 
the covariates declared as significantly used in the model are false discoveries. For all covariates µ´, 
¶  1, … , , we first sort ¿  , µ´0 in descending order to yield 	¿, ¶  1, … , . Then ».W  , µ´0, 
where µ´  74& Àj5: j5~ d1 - ∑ 	¿¿5¿/ k  ½Ã. The set of regions Ä¼ then can be claimed to be 
significant covariates based on an average Bayesian FDR of ½. 
 
3.3.6. Performance Assessment 
 We assess the performance of our method using cross-validation, i.e., we randomly split the data 
10 times into mutually exclusive training and test sets in the proportion 2:1, build the predictor using the 
training set, and then predict survival for the test set and compare it with the observed survival. We use 
two measures of predictive performance, the Brier score (BS) and the coefficient of determination (RW). 
The BS is a specialized measure of goodness-of-fit for survival models (Graf et al., 1999) and is given by 
 
BS	t  @ ∑ ÇdÈÉ	K|
Lk
[	KLÊ ËDE/
κÌ	KL P d~È
É	K|
Lk[	KL
κÌ	K Í@/ , 
 
where κÌ	· is the Kaplan-Meier estimate of the survival distribution for the observations 	t, … , t@ and [ 
denotes a indicator function. For BS we utilize the training data  and 
 to fit a model 	|
 and use it to 
obtain the survival distribution SÉ	t5|, 
5 for a future patient with covariate 
5. Brier score ranges from 0 
to 1 and the smaller the score the better is the fit. 
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 The RW measure is the usual coefficient of determination of the fitted model and is estimated as 
 
RW  1 - (& - W ,	)Ï - 	00, 
 
where 	· denotes the log-likelihood function. In order to obtain the RW, we first estimate Ï , the vector 
of latent covariate effects, using the median of the posterior distribution and then use it as a predictor in 
the univariable version of the specific underlying model. For example, the vector Ï  estimated from the 
AFT-Tree model is used as the predictor vector in a univariable AFT. RW also ranges from 0 to 1 and 
values close to 1 indicate good fits. 
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4. Results and Discussion 
4.1. Random Forest 
 Random Forest model was used to fit the binary responses (STS vs. LTS) of the patients studied 
here. We first performed a study about the parametric settings to run Random Forest models in R. The 
default setting for the randomForest function sets the number of trees (ntree) to 500 and the number of 
covariates sampled for each binary split (mtry) as the square root of the total number of covariates. In our 
case, mtry=12. The bigger the number of trees used to build the model, the better the fitting is expected to 
be, however it increases computational time. Similarly, sampling a small number of covariates as 
candidate for splitting the nodes of the trees can leave important covariates out, hence compromising the 
fitting. On the other hand, sampling a large number of covariates can populate the model with non 
informative covariates, resulting in overfitting and increasing of the computation time (Rodin et al., 
2009). We run Random Forest 10 times for different settings of the parameters ntree (50, 100, 200, 500, 
1000) and mtry (1, 3, 6, 12, 25, 50, 100, 144) and a summary of the misclassification error for the training 
data is presented in Table 2. Clearly, the misclassification error is smaller when the number of trees is 
equal to 1,000 as well as when the parameter mtry is equal to the default value already implemented in the 
R function.  
 Followoing, a Random Forest model was fitted and the binary responses (STS vs. LTS) of the 
patients studied here were predicted by this model. In order to reduce computation time and still obtain a 
small misclassification error, we opted by using the default parameters in the R function (ntree=500 and 
mtry=12). The overall misclassification rate of the prediction for the training set data (Table 2) was 18.9% 
(STS - 18.8% and LTS - 19%), and the overall misclassification rate for the testing set (OOB) was 25.3% 
(STS - 22.6% and LTS - 31.8%) indicating a slight overfitting in training set. Figure 5 allows a visual 
evaluation of the predictive performance of RF model. For 100% accuracy, one should find only red 
symbols at the left side of the dashed line and only black symbols at the right. Besides the inherent 
misclassification error, there is a large heterogeneity observed within classes which shows that splitting 
the survival response in a binary category might cause some loss of information. The AUC, another 
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measure of performance, obtained for the training data is 0.83 and for the testing set is 0.77 (Figure 6). A 
large misclassification error along with large heterogeneity presented within classes do not allow us to 
make any suggestion in order to change disease management.    
 The top 20 most important variables used to build the RF model are listed in Table 3. Some gene 
members of the top metagenes are highly related to the development of cancer/glioma phenotypes based 
on a search performed at the OMIM database (http://www.ncbi.nlm.nih.gov/omim/). The top 3 most 
important metagenes found by the RF method are the same found by the survival-ensemble methods and 
further investigation about them will be presented in the following sections. In addition, patient age is 
also a factor commonly found important by both classes of methods. 
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Figure 5: Plot comparing the observed survival times with classes predicted by the Random Forest 
model. Dots represent time of death and triangles represent censored times. Red symbols are observations 
predicted as STS and black symbols are observations predicted as LTS. The vertical dashed line indicates 
the value of 24 months used to discretize the survival time in STS vs. LTS. 
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Figure 6: ROC for training set (solid lines) and test set (dashed lines) showing the performance in 
classification of STS and LTS by the Random Forest model. 
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Table 2: Summary of the misclassification error obtained for the training set using different settings of 
the parameters ntree and mtry in the randomForest R function. Ten RF models were built using each 
combination of parameters and the mean and s.d. of the overall training set misclassification error are 
reported. Parameter ntree represents the number of trees to grow and mtry is the number of variables 
randomly sampled as candidates at each split. 
 
 
  
 
mtry 
ntree 
50 100 200 500 1000 
1 24.6±0.6 23.1±0.9 21.4±0.7 19.4±0.7 19.4±0.5 
3 24.1±0.8 22.8±1.1 21.9±0.8 19.1±0.6 18.9±0.5 
6 24.0±0.8 22.7±0.8 21.7±0.9 19.2±0.5 18.6±0.4 
12 24.0±1.3 23.4±0.6 21.4±0.4 18.9±0.6 18.5±0.5 
25 23.4±0.9 22.6±1.0 22.0±1.0 19.6±0.4 19.0±0.3 
50 23.7±1.0 22.5±0.7 22.0±0.8 20.1±0.5 19.8±0.2 
100 24.0±0.9 23.0±0.4 22.9±0.7 20.4±0.5 20.3±0.5 
144 23.9±0.9 23.1±1.2 22.8±0.7 20.6±0.4 20.2±0.4 
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Table 3: Top 20 covariates used to build the RF model. Starred values (*) indicate metagenes containing 
genes related to the cancer phenotype while double-starred values (**) indicate metagenes containing 
genes related to the development of glioma phenotype. The directionality (DIR) information shows the 
influence of the over-expression of a given metagene in the patient survival: "+" means that survival 
increases with the metagene over-expression and "" means that survival decreases with the 
upregulation. The measure of importance is the Gini index attributed to this covariate. 
 
Rank Covariate 
 
DIR Measure of 
importance 
Genes 
1 metagene82** + 15.34 ALDH2, DAAM2, SCG3, MXI1, RAP2A 
2 metagene99* + 14.68 ZCCHC24, GLUD1, ID4,SCN3A 
3 metagene52** + 10.49 C1QL1, OSBPL11, CLASP2, MPRIP, PHLPP, GARNL1, ID1, RBPJ, 
IMPDH2, LRP4, PIK3R1, RIN2, PID1, BAI3, SALL2, TTC3, C11orf2, 
4 metagene81  7.40 ADM, HSPA5, TNC, MAOB, C1S 
5 metagene141 + 
 
7.07 KCND2, ARHGAP12 
6 metagene127*  5.86 FSTL1, COL4A1,  IGKC, RP11-35N6.1 
7 metagene85 + 5.82 ATP9A, WASF3, TCEAL2, NAP1L3 
8 metagene92*  4.77 MDK, MFAP2, THBS4, TPBG, SERPINH1 
9 metagene60 + 4.64 SLC9A6, AKAP11, HSP90AB1, HMP19, GPRC5B, ATP6V1G2, 
TERF2IP, SH3GL2, USP11 
10 metagene83**  4.62 GADD45A, LY96, LAMP2, PLSCR1, RBP1, ISG15 
11 metagene55**  4.45 ARPC1B, IFITM2, CTSC, ADFP, SLC39A14, GUSB, HLA-DMA, 
IRAK1, SERPINE1, PLP2, RNASE1, SLN, SOD2, TUBB6, CD44 
12 metagene51 + 4.42 RTN3, PLEKHB1, RTN1, AGXT2L1, TSPAN7 
13 metagene45* + 4.12 CPE, APOE, PEA15 
14 Age  3.97  
15 metagene84 + 3.97 CIRBP, ABAT, LRIG1, ZBTB20, ZMIZ1, RASSF2 
16 metagene54  3.83 NDRG1, NCAN, F13A1, FN1, MSN, P4HB, PTX3, ACTA2, 
SERPING1, C1R, ACTN1, AKAP12 
17 metagene104 + 3.19 ALDOC, FXYD6 
18 metagene135* + 3.05 RPS23, TCF12 
19 metagene69  3.01 IGFBP2, IGFBP3, PLS3, RPN2, CAPNS1, SRPX 
20 metagene42  2.96 HOXC4, HOXC6, HOXC10, HOXC11 
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4.2. Survival Ensembles 
4.2.1. Performance Assessment using Breast Cancer Data 
 We compare the performance of our method with other survival prediction methods tailored for 
gene expression data as reviewed in van Wieringen et al. (2009). We use the breast cancer data set of 
Van't Veer et al. (2002 -- available at http://www.rii.com/publications/2002/vantveer.html), which 
contains gene expression profiles for 295 breast cancer patients and 5,057 gene expression values along 
with the patient survival outcomes. We reapply the best methods found by van Wieringen et al. (2009) 
ensuring that we work under the same conditions, i.e., the multivariable linear Cox Proportional hazard 
model (hereafter CPH) with top 10 genes obtained using a univariable Cox regression, the L1-penalized 
Cox regression (CPH-L1) of Tibshirani (1997), and the L2-penalized Cox regression (CPH-L2) of Gui & 
Li (2005). In addition, we ran a multivariable linear Weibull model with the top 10 most significant genes 
obtained by univariable Weibull models, as well as, multivariable linear AFT model with the top 10 genes 
pre-selected using a univariable AFT analysis. As in van Wieringen et al. (2009), we use the top 200 most 
significant genes obtained by the univariable underlying model to run our ensemble-model versions of 
accelerated failure time (AFT-TREE), Weibull (WEI-TREE), and Cox (CPH-TREE). A simple long chain 
(k=10,000 iterations) for each tree model with burning-in of the first half (5,000 samples) is enough to 
make inferences since different initial values do not alter chain convergence. The cross-validation 
procedure was repeated 10 times with the data being randomly split into training and test sets with a 2:1 
ratio. We use the training set to build the predictor and then assess the performance of competing methods 
using the test set. 
 Figure 7 summarizes our results for all the methods considered here. Based on Brier score (Figure 
7 - left), the methodology proposed here substantially outperforms the competing methods. Brier score for 
the ensemble-models is roughly 30% smaller than those for CPH-L1 and CPH-L2 methods, which were 
reported the top two performing methods in van Wieringen et al. (2009). In terms of 1 - RW, the tree-
based methods are best performing methods (lowest values) along with CPH-L2, which has a very high 
variability and its performance is highly dependent on the actual split of the data. Interestingly, other 
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ensemble methods such as bagging and random forest yielded a lower RW (i.e. higher 1 - RW) in the 
breast cancer data set compared to set of Bayesian ensemble models studied here (medians of RW equal to 
0.058 and 0.061, respectively, from van Wieringen et al., 2009). In summary, based on these 2 different 
evaluation measures, we believe that our proposed methodology indeed improves the survival prediction 
accuracy, which could be attributed to the added flexibility in accounting for additive and non-linear 
effects. 
 
Figure 7: Box plots of performance results for the Brier score (BS -- left) and 	1 - RW measure (right) 
applied to the breast cancer data. For both measures, the lower the value the better the performance of the 
method. 
 
 
 As we mentioned before, one of the advantages of ensemble-models is that it is possible to assess 
the importance of each covariate for survival prediction using the relative frequency of occurrence as 
explained in Section 3.3.5. Using a FDR cutoff of 0.2 we found that a total of 15 variables are significant 
in the AFT-TREE, 11 in the WEI-TREE, and 14 in the CPH-TREE. Three genes (CCT5; BCL2; IL8) are 
simultaneously listed for AFT-TREE and WEI-TREE, and only one (NDUFS6) for AFT-TREE and CPH-
TREE. Genes identified by the models could represent promising targets for further biological 
investigation. A search at the OMIM database (http://www.ncbi.nlm.nih.gov/omim/) confirmed that many 
of them are reported to be highly related to cancer development. For instance, BCL2 is known as one of 
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the strongest predictors of shorter overall survival in diffuse large-B-cell lymphoma patients (Lossos et 
al., 2004) and this gene also figures as a prognostic marker for breast cancer in Van't Veer et al. (2002) 
studies. Another example is the STK12 gene which is localized in a region that is frequently deleted in 
tumors and that contains tumor-related genes such as p53 (Tatsuka et al., 1998). Furthermore, BTG2 
(Boiko et al., 2006) is known as a major downstream effector of p53-dependent proliferation arrest in 
human fibroblasts while SESN1 gene expression is known to be modulated by p53 transcripts (Velasco-
Miguel et al., 1999). 
 
4.2.2. Application to the brain tumor data 
 The methods compared here include the multivariable linear versions of AFT, Weibull, CPH, and 
the proposed ensemble-model versions AFT-TREE, WEI-TREE, and CPH-TREE models. One long chain 
(k=10,000 iterations) for each tree model is enough for satisfactory convergence and the first half of 
samples is discarded to make inference. 
 The Brier score calculated for the AFT-TREE (tree model) is slightly better than the one for its 
multivariable linear version (AFT) (ÐÑÒÓ~ÓJÔÔ  0.118 Õ 0.01 vs. ÐÑÒÓ  0.119 Õ 0.02) as well as for 
the Weibull models (ÐÖÔ×~ÓJÔÔ  0.116 Õ 0.02 vs. ÐÖÔ×  0.112 Õ 0.02). On the other hand, the BS 
for the CPH models are essentially the same (ÐÙÚÛ~ÓJÔÔ  0.110 Õ 0.01 vs. ÐÙÚÛ  0.110 Õ 0.02). To 
further evaluate the predictive ability of our proposed models, we conducted a time-dependent AUC 
analysis (Figure 8) to compare the prognostic capacity of survival models in different binary splits of the 
survival response. Time-dependent AUC analysis is frequently used in the clinical literature (Cerhan et 
al., 2007) to help physicians to better categorize patients in terms of survival classes. Here, the proposed 
ensemble-models do remarkably better than the competing methods showing higher sensitivity. 
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Figure 8: Time-dependent AUC analysis. Figure shows the time-dependent AUC analysis comparing the 
performance of the proposed ensemble methods with their multivariable linear versions applied to the test 
data. Dots represent the medians across splits of training/test sets and the lines depict the interquartile 
limits. Left plot: CPH (dashed lines) and CPH-TREE (solid); Center plot: WEI (dashed) and WEI-TREE 
(solid); Right plot: AFT (dashed) and AFT-TREE (solid). 
 
 A very small number of covariates (Table 4) are significantly used in the AFT-TREE, WEI-
TREE, and CPH-TREE models (Figure 9). There is a complete overlapping between the first 3 more 
important covariates in all models. In addition, the top five mostly used covariates by AFT-TREE and 
WEI-TREE are the same. Tumor grade is known as one of the most important clinical factors for 
predicting survival time in brain tumor patients (see section 1) and it was confirmed in our results as one 
of the covariates more frequently used by all models. Indeed, the level IV of the covariate tumor grade 
(GBM patients) has a distinct survival curve than the levels II and III corroborating previous findings 
(Figure 10). In addition, patient age, another important clinical covariate (see section 1), also figures in 
the top for the AFT-TREE and WEI-TREE models. Glioma patients studied here which are younger than 
the median age (52 years) present much better prognosis than patients older than 52 years of age (Figure 
11). 
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Figure 9: Posterior probability of a variable appearing in the CPH-TREE (top), WEI-TREE (center), and 
AFT-TREE (bottom) survival ensemble models for the brain tumor data. Covariates from left to right: 
patient age, tumor grade, metagene 1, ..., metagene 142. Variables with posterior probability above the 
horizontal gray line are considered to be significantly used when controlling the FDR at 20%. 
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Figure 10: Survival curves (solid) along with the 95% C.I. (dashed) for the gliomas patients studied here. 
P-value was obtained by a log-rank test. A total of 44 patients are classified as tumor grade II, 120 as 
grade III, and 570 as grade IV. 
 
 
 
Figure 11: Left: Age distribution; Right: K-M survival curves (solid) along with 95% C.I. (dashed) for 
patients younger and older than the sample median age (52 years). P-value was obtained by a log-rank 
test.  
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Table 4: Significant covariates (overall FDR of 20%) used to build the survival-ensemble models along 
with its probabilities p	´ of being included in the final model. Starred values (*) indicate metagenes 
containing genes related to the cancer phenotype while double-starred values (**) indicate metagenes 
containing genes related to the development of glioma phenotype. (+) means that survival increases with 
the metagene over-expression and (-) means that survival decreases with the upregulation. 
 
AFT  p	´ Weibull  p	´ CPH  p	´ 
metagene99* (+) 0.029 Grade  0.032 Grade  0.082 
Grade  0.028 metagene99* (+) 0.030 metagene52** (+) 0.037 
Age  0.020 metagene82** (+) 0.018 metagene99* (+) 0.036 
metagene82** (+) 0.017 metagene52** (+) 0.014 metagene139* () 0.030 
metagene52** (+) 0.013 Age  0.009 metagene70** (+) 0.021 
metagene116 () 0.011 metagene141 (+) 0.007    
metagene141 (+) 0.008 metagene85 (+) 0.005    
metagene50 () 0.007 metagene45* (+) 0.005    
metagene97* (+) 0.005       
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 Metagenes 52 and 99 were also found to have one of the highest posterior probabilities of being 
used in all survival-ensemble models as well as the RF model. Metagene 82 appeared frequently used in 
the AFT-TREE, WEI-TREE, and RF models while metagene 70 was more frequently used than other 
variables to build the CPH-TREE model. A following search at the OMIM database 
(http://www.ncbi.nlm.nih.gov/omim/) revealed that these metagenes contain genes known to be associated 
with the development and progression of many tumors including many associated to brain tumor 
development as the ones discussed in the section 1. For example, patients having values of expression of 
metagene 52 above the median show significantly better prognostic curves (Figure 12A). A detailed 
search shows that the metagene 52 has six genes associated to cancer phenotype: PHLPP, GARNL1, ID1, 
RBPJ, PIK3R1, and BAI3 (Figure 12B). PHLPP is known for its capacity to dephosphorylate AKT, 
triggering apoptosis and suppressing tumor growth via the p53 and RTK mitogenic pathways. PHLPP 
appears downregulated in several colon cancers and glioblastoma cell lines (Gao et al., 2005). In our 
study, PHLPP also appears downregulated in patients with shorter survival (Figure 12B). Mouse 
embryocarcinoma cells upregulated GARNL1 expression following induction of neuronal differentiation 
(Heng & Tan, 2002). We show that the gene GARNL1 is upregulated in long survival patients (Figure 
12B) and hypothesize that the role of this gene in promoting neuronal differentiation prevents cells going 
through migration or invasion processes, hence improving prognosis. The protein ID1 is a negative 
transcriptional regulator of CDKN2A, which is associated with the development of malignant melanoma 
(Ohtani et al., 2001). CDKs, as discussed in section 1, are important members of the mitogenic pathway 
which control cell proliferation. We show (Figure 12B) that ID1 is overexpressed in long survival patients 
and hence we hypothesize that ID1 also negatively regulates CDKs and controls cell proliferation. RBPJ 
is known to be part of the Notch pathway. Activation of the Notch cascade is known to maintain the 
undifferentiated state in cells (van Es et al., 2005) and as a result, it might be directly related with 
mesenchymal phenotypes in gliomas. In addition, the Notch pathway plays a role in neuronal function 
and development and stabilization of angiogenesis. Hence, the underexpression of RBPJ in short survival 
patients (Figure 12B) suggests alterations in the Notch pathway causing the formation of mesenchymal 
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and angiogenesis phenotypes. In addition, it is known that close to 90% of GBM present the PIK3R1 
signaling pathway altered (TCGA, 2008) and BAI3 (Brain-specific angiogenesis inhibitor 3) is considered 
to play a role in suppression of glioblastoma since its expression is absent or significantly reduced in this 
tumor type (Shiratsuchi et al., 1997). 
 Also, patients having values of expression of metagene 70 above the median show significantly 
better prognostic curves (Figure 13A). Metagene 70 contains the genes EGFR, FAIM2, SASH1, and 
PINK1. The EGFR gene is involved in cell signaling, cell proliferation, differentiation, motility, and in 
tissue development (Wang et al., 2004) which makes it one of the most important genes related to the 
development of gliomas (see section 1). In our study we show that patients with upregulated EGFR 
(Figure 13B) tend to survive less than other patients. In addition, the gene FAIM2 which is a FAS 
receptor for a tumor necrosis factor (TNF) (Somia et al., 1999) is found altered (Figure 13B). FAS is a 
“death-receptor”, as discussed in section 1, which is involved in pro-apoptotic and anti-apoptotic roles. 
The gene SASH1 which is downregulated in breast tumor tissues (Zeller et al., 2003) is also 
downregulated in short survival glioma patients (Figure 13B), and the gene PINK1 which is a PTEN-
induced putative kinase is also downregulated in short survival glioma patients (Figure 13B) suggesting 
alterations in the mitogenic signaling and apoptotic pathways. 
 Likewise, patients presenting downregulation of metagenes 82 (Figure 14A) and 99 (Figure 15A) 
show significantly better prognostic curves than other patients. Metagene 82 contains the gene MXI1 
which negatively regulates MYC oncoprotein, an important glioblastoma tumor inductor (Albarosa et al., 
1995). MYC plays an important role in regulating cell proliferation, apoptosis (controls the death-receptor 
Bcl-2), and cell differentiation (Albarosa et al., 1995). We show that glioma patients with short survival 
present downregulation of MXI1 (Figure 14B) suggesting that the MYC oncoprotein is overexpressed 
and, hence, causing cell proliferation, apoptotic, and mesenchymal phenotypes. To conclude, metagene 99 
contains the gene ID4 which is believed to be a putative leukemia suppressor (Yu et al., 2005) and here 
appears overexpressed in long term survival patients (Figure 15B) suggesting an equivalent role in brain 
tumor suppression as well. 
  
Figure 12: Metagene 52 — (A) K-
obtained by log-rank test. (B) Heatmap of the expression values of genes grouped within metagene 52. 
Red color spots represent over-expressed values and green color spots represent 
Samples are depicted in the horizontal axis and are sorted by survival time (from 
shorter survival times). Genes are depicted in the vertical axis. Dendrogram was obtained by 
method. 
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 Figure 13: Metagene 70 — (A) K-
obtained by log-rank test. (B) Heatmap of the expression values of genes grouped within metagene 70. 
Red color spots represent over-expressed values and green color spots represen
Samples are depicted in the horizontal axis and are sorted by survival time (from left to right: 
shorter survival times). Genes are depicted in the vertical axis. Dendrogram was obtained by 
method. 
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Su
rv
 
pr
o
b
(A)
47 
 
M survival curves (solid) along with 95% C.I. (dashed). P
t under
1 2 3 4 5 6 7
log(weeks)
MG expression < median
MG expression > median
P<.001
 
-value was 
-expressed values. 
longer to 
"Ward" 
 Figure 14: Metagene 82 — (A) K-
obtained by log-rank test. (B) Heatmap of the expression values of genes grouped within metagene 82. 
Red color spots represent over-expressed values and green color spo
Samples are depicted in the horizontal axis and are sorted by survival time (from left to right: 
shorter survival times). Genes are depicted in the vertical axis. Dendrogram was obtained by 
method. 
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 Figure 15: Metagene 99 — (A) K-
obtained by log-rank test. (B) Heatmap of the expression values of genes grouped within metagene 99. 
Red color spots represent over-expressed values and gre
Samples are depicted in the horizontal axis and are sorted by survival time (from left to right: 
shorter survival times). Genes are depicted in the vertical axis. Dendrogram was obtained by 
method. 
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 Additionally, partial dependence (PD) functions (Friedman, 2001) obtained by the 
marginalization of the posterior distribution of #	
 with respect to the covariate(s) of interest are 
particularly useful to illustrate the marginal effect of one relevant covariate(s) directly on the survival 
outcome as in the AFT-TREE model. PD function plots (Figure 16) shows that marginal effects of the 
metagenes 52, 82, and 99 on the survival time estimated by the AFT-TREE model. It shows that the 
relative upregulation of metagene 52 increases the brain tumor patient survival time in roughly 170 weeks 
(3.3 years), the relative upregulation of metagene 82 increases glioma patients survival in 130 weeks (2.5 
years), and the regulation of the metagene 99 between values 2 and 4 increases the survival of glioma 
patients in almost 200 weeks (around 4 years). However, just a few patients have these metagenes 
upregulated (> 4) which makes the confidence intervals bigger at this region, indicating that the 
interpretation of the PD plots at this region must be done with caution. Another important tool used to 
identify individual contributions of the covariates on the patient survival time are nomograms. In Figure 
17 we show a nomogram of the most important variables in the AFT-TREE model. The interpretation is 
performed as following. Identify the patient age and draw a vertical line to the "points" axis on the top of 
the nomogram. Repeat this process for the remaining variables. Sum the points for each individual 
variable and locate this on the "Total Points" axis at the bottom of the page. The width of a variable axis 
represents how much it affects the overall survival time. To calculate the log of survival time in weeks, 
draw a vertical line from the "Total Points" spot on the linear predictor axis. Indeed our results show that 
expression values of metagenes drastically impact the overall survival in brain tumor patients in addition 
to clinical covariates. For example, a patient indexed by the median values of the most important 
covariates found by the AFT-TREE model, i.e., a patient 52 years of age, presenting tumor grade IV, 
metagene 52 expression equal to -0.36, metagene 82 expression equal to -0.95, and metagene 99 
expression equal to -0.75 will receive a "Total points" score around 93 and its expected survival time will 
be of 75-80 weeks. 
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Figure 16: Partial dependence (PD) plots for metagene 52, 82, and 99 in the AFT-TREE model. Solid 
lines represent the marginal contribution to the survival time and dashed lines are 95% C.I. 
 
 
 
Figure 17: Nomogram of the most important variables in the AFT-TREE model. 
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5. Conclusion 
 We built a model for binary response using the Random Forest model. Random Forest is a tree-
based ensemble method with high predictive accuracy commonly seen in the Biostatistics literature. We 
obtained a misclassification error of 19% for training data and 25% for testing data. We also present and 
discuss a list of the variables most frequently used to build the trees in the RF method. Besides the 
unavoidable misclassification error, we show that splitting the response in categories (STS vs. LTS) might 
cause loss of information since the heterogeneity within classes is relatively large. 
 We have proposed Bayesian ensemble methods for survival prediction in the high-dimensional 
context as in DNA microarray data analysis. We relied on a powerful Bayesian predictive tool (BART) to 
estimate the covariate effects by means of a latent variable assumed to be normally distributed. BART 
was chosen because it is flexible to accommodate a high number of covariates and their interactions and 
properly accounts for the uncertainty of parameter estimation inherent to the Bayesian approach. 
Nonetheless, the proposed method can be extended to allow the use of any other ensemble method 
instead. 
 We incorporated the latent variable estimates in three widely used survival models, named AFT, 
Weibull, and CPH, and performed Bayesian estimation of additional parameters simultaneously. Our 
prior choices require less complex MCMC sampling techniques and sometimes, undesirable parameters 
could be integrated out, as the baseline hazard function in the CPH-TREE model. In addition, our method 
provides prediction of the survivor function which directly contributes to an adequate personalized 
management of patients. 
 The application of our methodology to two different data sets showed that our model outperforms 
prediction accuracy of many available models. 
 The screening ability of BART identifies important predictors across trees and training-test splits 
of data, which allowed us to reveal the impact of many important genes and clinical covariates on the 
survival of glioma patients. In addition to the predictive ability, the variable selection procedure along 
with PD functions and nomogram techniques grants high interpretability to the final model. 
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